Tanner A R, Halliday J W, Powell L W
Department of Medicine, University of Queensland, Royal Brisbane Hospital, Australia.
Scand J Immunol. 1980;11(3):335-40. doi: 10.1111/j.1365-3083.1980.tb00242.x.
The influence of prednisolone on monocyte chemotactic activity in vitro at prednisolone concentrations comparable with those achieved in man following oral dosage has been investigated. Chemotactic activity of monocytes from each of sixteen normal subjects was suppressed by concentrations of prednisolone as low as 25 ng/ml (suppression of chemotaxis, 20%). Maximal suppression occurred at 100 ng/ml (suppression of chemotaxis, 48%) and no significant increase in suppression was produced by increasing the concentration to 200 ng/ml (suppression of chemotaxis, 53%). In contrast, monocytes isolated from ten patients receiving corticosteroid therapy showed no significant suppression of chemotactic activity when exposed to these concentrations of prednisolone, even though they exhibited a normal ability to respond to a chemotactic stimulus. The lack of suppression of monocyte chemotaxis in patients receiving corticosteroid therapy is unexplained, but may represent a change in the circulating monocyte or lymphocyte populations.
已研究了泼尼松龙在体外对单核细胞趋化活性的影响，其浓度与口服给药后人体达到的浓度相当。来自16名正常受试者的单核细胞趋化活性被低至25 ng/ml的泼尼松龙浓度所抑制（趋化性抑制率为20%）。最大抑制发生在100 ng/ml（趋化性抑制率为48%），将浓度增加到200 ng/ml时抑制作用无显著增加（趋化性抑制率为53%）。相比之下，从10名接受皮质类固醇治疗的患者中分离出的单核细胞，在暴露于这些浓度的泼尼松龙时，趋化活性未显示出显著抑制，尽管它们对趋化刺激表现出正常的反应能力。接受皮质类固醇治疗的患者单核细胞趋化性缺乏抑制的原因尚不清楚，但可能代表循环单核细胞或淋巴细胞群体的变化。
